医疗机构药学服务中的中药药物警戒实践探讨

doi:10.19803/j.1672-8629.2021.05.05

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (5): 422-426.
DOI: 10.19803/j.1672-8629.2021.05.05

• 中药药物警戒研究与实践专栏 • 上一篇下一篇

医疗机构药学服务中的中药药物警戒实践探讨

萨日娜^1,2,3, 张冰^1,2,*, 林志健^1,2, 王晓芳¹, 张晓朦^1,2

¹北京中医药大学中药学院,北京 102488;
²北京中医药大学中药药物警戒与合理用药研究中心,北京 102488;
³甘肃省人民医院,甘肃兰州 730000

收稿日期:2020-02-26 出版日期:2021-05-15 发布日期:2021-05-12
通讯作者: ^*张冰,女,博士,教授,主任医师,中药药物警戒与合理用药研究、中药药性理论与名老中医传承研究、中药防治代谢性疾病研究。E-mail:zhangbing6@263.net
作者简介:萨日娜,女,在读博士,中药药物警戒与合理用药研究。
基金资助:
国家自然科学基金项目（81874349）;国家中医药领军人才支持计划“岐黄学者”项目;第三批国家高层次人才特殊支持计划（万人计划）教学名师项目;北京中医药大学创新创业教育2020年“专创融合”项目（1120063520023）

Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions

SA Rina^1,2,3, ZHANG Bing^1,2,*, LIN Zhijian^1,2, WANG Xiaofang¹, ZHANG Xiaomeng^1,2

¹School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China;
²Center for Pharmacovigilance and Rational Use of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China;
³Gansu Provincial Hospital, Lanzhou Gansu 730000, China

Received:2020-02-26 Online:2021-05-15 Published:2021-05-12

摘要/Abstract

摘要： 目的探讨医疗机构如何结合药学服务岗位开展中药药物警戒实践。方法通过文献综述和课题组前期临床调研结果,梳理医疗机构药学服务现状和中药药物警戒中存在的问题,结合本课题组20余年的中药药物警戒研究成果,探讨药学服务岗位中的中药警戒实践。结果医疗机构是我国实施药物警戒的基层单位,其药学服务水平是保障药物警戒实施的基本要素。结论提出应重视中药药物警戒在医疗机构药学服务中的作用,加强中药药物警戒能力建设,构建以医疗机构临床药师为主体,以药物警戒为切入点,探索全程化药学服务的实践模式。

关键词: 医疗机构, 中药, 药物警戒, 药学服务

Abstract: Objective To explore medical institutions carry out traditional Chinese medicine(TCM) pharmacovigilance practice combined with pharmaceutical service. Methods Through literature review and preliminary clinical research results, the current situation of pharmaceutical care and the problems of pharmacovigilance of TCM in medical institutions were mastered. Based on the results of pharmacovigilance of TCM in our research group, the risk of pharmacovigilance of TCM in pharmaceutical care posts was refined and practiced. Results Medical institutions were the basic units to implement pharmacovigilance in China, and their pharmaceutical care level is an important guarantee for the implementation of pharmacovigilance. Conclusion Attention should be paid to the role of pharmacovigilance of TCM in pharmaceutical care in medical institutions and strengthen the pharmacovigilance of Chinese medicine. A practical model should be established with clinical pharmacists in medical institutions as the main body and pharmacovigilance as the breakthrough point to carry out the whole-process pharmaceutical care.

Key words: medical institutions, traditional Chinese medicine(TCM), pharmacovigilance, pharmaceutical care

中图分类号:

R28R944.11

萨日娜, 张冰, 林志健, 王晓芳, 张晓朦. 医疗机构药学服务中的中药药物警戒实践探讨[J]. 中国药物警戒, 2021, 18(5): 422-426.

SA Rina, ZHANG Bing, LIN Zhijian, WANG Xiaofang, ZHANG Xiaomeng. Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 422-426.

参考文献

[1] Zeng FD.Medical quality management and responsibility of clinical pharmacy[J].Herald of Medicine(医药导报),2017,36(11):1215-1218.
[2] Gao Y,An H,Xu MH,et al.Brief introduction to Chinese medicine pharmacovigilance[J].Chinese Journal of Basic Medicine in Traditional Chinese Medicine(中国中医基础医学杂志),2019,25(2):233-234.
[3] NHC National Health Commission of the People's Republic of China.statistical bulletin of health development in China 2019[EB/OL].(2020-06-06)[2021-01-15].http://www.nhc.gov.cn/guihuaxxs-s10748/202006/ebfe31f24cc145b198dd730603ec4442.shtml.
[4] Chinese Hospital Association.Notice on further strengthening the construction of clinical pharmacist system[EB/OL].(2016-11-28)[2021-01-15].http://www.cha.org.cn/plus/view.php?aid=15129.
[5] Zhou JF,Sun CJ.The development status and trend of hospital pharmacy service[J].Chinese Manipulation &Rehabilitation Medicine(按摩与康复医学),2021,12(2):83-86.
[6] Zhao N,Zhao R,Liu LH.Analysis on the current situation and requi-rements of pharmaceutical services in public hospitals in China[J].Clin-ical Medication Journal(临床药物治疗杂志),2020,18(11):78-81.
[7] National Health Commission of the People's Republic of China,National administration of traditional Chinese medicine.Opinions on accelerating the high quality development of pharmaceutical services[EB/OL].(2018-11-28)[2021-01-15].http://www.gov.cn/xinwen/2018-11/28/content_5344128.htm.
[8] Zhang B,Jin R,Wu JR.A course building of clinical Chinese medicine based on the knowledge framework of modern clinical pharmacists of Chinese medicine[J].Pharmaceutical Education(药学教育),2011,27(5):23-25.
[9] Wu JR,Zhang B.Discussion of traditional Chinese medicine pharmacovigilance[J].Chinese Journal of Pharmacoepidemiology(药物流行病学杂志),2009,18(5):312-315.
[10] Zhao X,Leng ML,Wang P,et al.Research on current status and countermeasures of information collection on adverse drug reactions by drug manufacturers from medical institutions in China[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(11):652-657.
[11] Feng YN,Liu XX,Li YH,et al.Challenges to pharmacovigilance by medical institutions under the new drug administration law[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(9):572-573.
[12] Sun XX.Analysis and thinking on the current situation of rational use of traditional chinese medicine based on the concept of pharmaceutical care(基于药学报务理念的基层医生中药合理用药现状分析与思考)[D].Beijing:Beijing University of Traditional Chinese Medicine,2017.
[13] Wang Y,Lin ZH,Dong YZ,et al.Investigation of pharmaceutical services for traditional Chinese medication precautions in medical institutions[J].China Pharmacist(中国药师),2018,21(12):2133-2139.
[14] Tian LJ.Research on the history of modern chinese pharmacy(中国现代药学史研究)[D].Shenyang:Shenyang Pharmaceutical University,2006.
[15] Chen F,Yang SM.Chen F,et al.Status and problems of ADR monito-ring system in china[J].Herald of Medicine(医药导报),2006(5):486-488.
[16] Lou S,Tang SL.Discussion on problems encountered by clinical pharmacists of traditional Chinese medicine and improvement measures[J].Pharmacy and Clinics of Chinese Materia Medica(中药与临床),2020,11(3):21-23.
[17] Guan G,Ru SS,Rong CL.Role and work connotation of clinical pharmacists in rational application of traditional Chinese medicine in primary Chinese medicine hospitals[J].Journal of Community Medicine(社区医学杂志),2018,16(21):1589-1591.
[18] Lin P,Ma KF,Song SZ,et al.Specification for pharmaceutical care in medical institutions Part 2 prescription review[J].China Pharmacy(中国药房),2019,30(23):3176-3177.
[19] Jin R,Zhang B.Theory and practice of comment on prescription of chinese patent medicine(中成药处方点评的理论与实践)[M].Beijing:People's Medical Publishing House,2019.
[20] Zhang B.Chinese medicine pharmacovigilance(中药药物警戒)[M].Beijing:People's Medical Publishing House,2015.
[21] Tan WJ,Jing ZH,Li QZ,et al.Specification for pharmaceutical care in medical institutions part 6 pharmaceutical ward round[J].China Pharmacy(中国药房),2019,30(24):3316-3318.
[22] Hou WJ,Pu YS,Jin ZH,et al.Specification for pharmaceutical care in medical institutions part 7 medication monitoring[J].China Pharamacy (中国药房),2019,30(24):3318-3321+3324.
[23] Yan XL,Dai TT,Wang CH,et al.Specification for pharmaceutical care in medical institutions part 3 medication reconciliation[J].China Pharamacy(中国药房),2019,30(23):3178-3180.
[24] Xin BW,Gu WY,Shi KR,et al.Discussion on the present situation of Chinese medicine consultation and medication education[J].World Latest Medicine Information(世界最新医学信息文摘),2019,19(96):269-270.
[25] Du LP,Fan P,Jing ZH,et al.Specification for pharmaceutical care in medical institutions part 5 medicine education[J].China Pharamacy(中国药房),2019,30(24):3315-3316.
[26] Yang LY,Du S,Li XY,et al.Specification for pharmaceutical care in medical institutions part 1 pharmacist-managed clinic[J].China Pharamacy(中国药房),2019,30(23):3174-3175.

医疗机构药学服务中的中药药物警戒实践探讨

Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[2]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[3]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[4]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[5]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[6]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[7]	李舒冉, 郭姗姗, 冀祖恩, 张薇, 崔晓兰. 新型冠状病毒感染后认知功能障碍的研究现状[J]. 中国药物警戒, 2024, 21(1): 59-64.
[8]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[9]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[10]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[11]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[12]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[13]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[14]	梅雨, 朱越, 张慧婷, 肖成荣, 高月, 马增春. 基于网络药理学和实验验证探讨中药复方CB001对低剂量辐射防护的作用机制[J]. 中国药物警戒, 2023, 20(8): 872-879.
[15]	张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910.